- LIXTE Biotechnology Holdings Inc LIXT noted that a team of scientists reported that in three difficult-to-treat cancer types, LIXTE’s lead compound, LB-100, combined with an inhibitor of the WEE1 kinase, causes unexpectedly effective cancer cell killing.
- Most surprisingly, when cancer cells acquire resistance to this combination therapy, they have highly reduced cancer-causing capacity in animal models.
- This observation indicates that LB-100 combination therapy can force cells to give up their cancer-causing properties to acquire drug resistance.
- Related: Lixte Biotech Shares Jump Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers.
- John Kovach, CEO and Founder of LIXTE and a co-author of the report, said the treatment of cancer cells with Lixte’s lead clinical compound, LB-100, rather than inhibiting, further stimulates the signals that drive cancer cell proliferation, but paradoxically, impeding cell proliferation.
- Dr. Kovach continued, “The authors also show that combination of LB-100 with an inhibitor of WEE1, a regulator of stress responses in the cell, leads to highly efficient cancer cell death in three hard-to-treat cancer models: colorectal, pancreatic, and bile duct carcinomas.”
- The combination of LB-100 and WEE1 inhibition suppressed the growth of patient-derived tumors refractory to conventional therapies and was associated with only modest toxicity in animal models.
- Price Action: LIXT shares are up 146% at $2.00 on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
